Repros gets the nod to proceed in clinical trials

|About: Repros Therapeutics Inc. (RPRX)|By:, SA News Editor

The FDA notifies Repros Therapeutics (RPRX) that it may proceed with phase 1 and phase 2 studies for Proellex under separate INDs for endometriosis and uterine fibroids while remaining on partial clinical hold.

The maximum allowed dose will be 12 mg daily.

Consensus 2015 revenue estimate is $16.8M.

133 mutual funds have positions, up from 120 a year earlier.